Michael Moroney is the Director of Communications at the Franklin Center for Government and Public Integrity.
FORBES: Most Young People Are Really Lousy Political Investors
Moroney from Dow Theory Forecasts recently took Microsoft out of his top 20 "focus list" stocks.
Recently, Richard Moroney, editor of the Upside investment newsletter, has been touting Primoris as good buy.
Click here for instant access to all October recommendations from Richard Moroney, editor of Upside.
FORBES: Southwest Shares Are Tempting But Airline Stocks Usually Don't Fly
"We're telling people, if they can, find shelter elsewhere, " said Edward Moroney, a Brick Township spokesman.
Click here to read about all six severely undervalued stocks profiled this month by Richard Moroney in Upside.
Moroney likes the growth in profit margins and the surge of online business.
Moroney evaluates stocks with a quantitative model that ranks companies by several measures of financial and stock price performance.
Pawn service charges, points out Moroney, rose 55%, while jewelry-scrapping revenue climbed 89%.
According to Richard Moroney, the single area of concern for investors is hardware.
Click here to see what Editor Rich Moroney has to say about Ceradyne with a free trial of Upside.
Click here for more of Moroney's current best buys in Dow Theory Forecasts.
Richard Moroney, editor of the Dow Theory Forecasts , believes that this momentum will continue due to strengthened financials.
FORBES: Steady Economic Growth Means Big Gains For This Coal Producer
One small-cap with the highest possible overall score of 100 that Moroney recommends in his Upside newsletter is EZCORP.
Special Offer: Freport McMoran is up 30% since Oct. 27, the day after Richard Moroney urged readers to buy it.
The company is still expanding aggressively, Moroney says, planning to boost its number of stores by 60% to 6, 000 by 2010.
Based on Anheuser-Busch's track record of delivering profit growth and its dominant market position, Moroney rates the stock a long-term buy.
Richard Moroney of Dow Theory Forecasts urges investors to continue to look beyond drug stocks for this year's best buys.
Richard Moroney, editor of the Dow Theory Forecasts investment newsletter, recently recommended BBBY as a long-term buy for his subscribers.
Yes, says Richard Moroney, editor of the Dow Theory Forecasts newsletter.
Dennis Moroney of TowerGroup, a research firm, predicts that issuance volumes for 2007 will end up being 25% higher than last year.
With products from Band-Aids to stents to cancer drugs in development, Moroney says the company is well positioned to continue its steady growth.
"Per-share earnings have topped the consensus estimate in each of the last four quarters, by an average of roughly 8 cents, " adds Moroney.
Moroney makes his investment recommendations combining Dow Theory market timing with a quantitative model that seeks stocks with characteristics that the market rewards.
Moroney believes Pfizer's drug pipeline--which includes drugs for asthma, smoking cessation, cancer and osteoporosis--should offset stiff competition from generic-drug makers in aging product lines.
Richard Moroney, editor of Upside, an investment newsletter focused on investing in small- and mid-cap stocks, believes that JDA is due for growth.
FORBES: Supply-Chain Management Software Maker Leverages The Cloud
Also high on Moroney's "buy" list is Pfizer (nyse: PFE - news - people ), which trades at 20 times expected earnings.
Moroney likes the company's clear and simple model and consistent growth.
Click here for updates and more in-depth analysis from Richard Moroney.
应用推荐